Firm Using AI to Transform Clinical Trials Sees Share Price Gain

Sponsored:

Monday, December 9, 2024

AI is everywhere— and this company’s process is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. News that it has entered into a pilot collaboration agreement with a Top 5 pharmaceutical company is sending shares higher.

Premier artificial intelligence company NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) is transforming clinical trials in the pharmaceutical industry. Today, the firm announced in a press release that it had entered into a pilot collaboration agreement with a top 5 pharmaceutical company. The pilot seeks to unlock novel insights and hypotheses regarding patient populations to facilitate the development of new therapeutics for autoimmune disorders.

As part of this collaboration, NetraMark will comprehensively review the provided data to generate recommendations derived from the robust methods and subpopulation analyses in which the NetraAI technology excels. These analyses will focus on critical research areas, including the impact of medications, surgical and medical intervention history, and refining autoimmune disorder subtypes.

NetraMark’s NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Its product offering uses a novel topology-based algorithm that simultaneously parse patient data sets into subsets of strongly related people according to several variables.  U.S. shares were up over 30 percent in afternoon trade.

Sponsored: